Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35840 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3268310 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11878863 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL6530072 | 0.77 | ALDH1A1 (0.38) | TDP1ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL27631768 | 0.77 | TDP1 (0.36) | TDP1ALDH1A1TSHRFGFR4LMNA | |
| SCHEMBL531565 | 0.77 | ALDH1A1 (0.38) | TDP1ALDH1A1TSHRFGFR4LMNA | |
| Hydrochloric Acid SCHEMBL6419361 | 0.76 | ALDH1A1 (0.36) | TDP1ALDH1A1TSHRFGFR4 | |
| SCHEMBL5708939 | 0.76 | TDP1 (0.35) | TDP1ALDH1A1TSHRFGFR4 | |
| SCHEMBL9772444 | 0.75 | LMNA (0.37) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL27789841 | 0.74 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 751 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118043077-A | Drug-loaded single-molecule nano polymer, prodrug, micelle, drug delivery system, preparation method and application | 嘉兴清准医药科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117500822-A | Polynucleotide capable of enhancing protein expression and use thereof | 生物欧赛加有限责任公司 | 2024-02-02 | — | — | CN | claimed |
| CN-114983926-B | Detachable soluble microneedle for promoting skin and hair regeneration and preparation method thereof | 南方医科大学南方医院 | 2024-01-26 | — | — | CN | claimed |
| CN-112153957-B | Use of microneedle patch for promoting hair growth | 北卡罗来纳州立大学 | 2023-12-26 | — | — | CN | claimed |
| CN-116981484-A | Use of miRNA-485 inhibitor to regulate expression of PSD95, synaptorin and caspase 3 | 生物欧赛加有限责任公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116963722-A | Micelle nanoparticle and use thereof | 生物欧赛加有限责任公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116963755-A | Modified interleukin 2 (IL-2) polypeptides and methods of making and using the same | 赛缇姆治疗公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116963785-A | Use of miRNA-485 inhibitors for treating diseases or conditions associated with aberrant NLRP3 expression | 生物欧赛加有限责任公司 | 2023-10-27 | — | — | CN | claimed |
| CN-112638348-B | Method and composition for stabilizing nanogels and dental compositions produced from nanogels | 登士柏希罗纳有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-116829132-A | Micelle nanoparticle and use thereof | 生物欧赛加有限责任公司 | 2023-09-29 | — | — | CN | claimed |
| US-7053150-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-05-30 | — | — | US | claimed |
| WO-2005058367-A2 | PEGYLATED SMALL MOLECULES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-06-30 | — | — | WO | claimed |
| US-20050136031-A1 | Drugs covalently attached to a water-soluble oligomer; reduced first pass effect; e.g. non-opioid antagonist conjugated to a polyethylene glycol (PEG) group such as PEG-naloxol | REDHILL BIOPHARMA LTD. (IL) | 2005-06-23 | — | — | US | claimed |
| US-6855744-B2 | Gelcasting polymeric precursors for producing net-shaped graphites | UT-BATTELLE, LLC (US) | 2005-02-15 | — | — | US | claimed |
| US-20040236015-A1 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS | 2004-11-25 | — | — | US | claimed |
| US-6491891-B1 | MOLDING CERAMIC POWDERS IN THE PRESENCE OF POLYMER BLENDS AS BINDERS, TO FORM CARBON COMPOSITES HAVING HIGH DENSITY, STRENGTH, THERMOCONDUCTIVITY, FRICTION, HEAT AND WEAR RESISTANCE | UT-BATTELLE, INC. | 2002-12-10 | — | — | US | claimed |
| EP-0465302-B1 | Precursors of isocyanurate polymers having hydroxyl, urethane, isocyanate or acrylate groups, and process for their preparation | ATOCHEM ELF SA (FR) | 1994-12-28 | — | — | EP | claimed |
| US-4411987-A | SILVER HALIDE EMULSION CONTAINING GLYCOLURIL COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1983-10-25 | — | — | US | claimed |
| US-4101461-A | Method for preparation of anion exchangers by substitution of hydrophilic polymeric gels | CZECHOSLOVENSKA AKADEMIE VED (CS) | 1978-07-18 | — | — | US | claimed |
| US-3991018-A | Method for preparation of cation exchangers by substitution of hydrophilic polymeric gels of crosslinked hydroxyalkyl acrylates and hydroxyalkylacrylamides | CESKOSLOVENSKA AKADEMIE VED (CS) | 1976-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136031-A1 | Drugs covalently attached to a water-soluble oligomer; reduced first pass effect; e.g. non-opioid antagonist conjugated to a polyethylene glycol (PEG) group such as PEG-naloxol | OPRM1, OPRL1, OPRK1 | TDP1 4453/4885ALDH1A1 1511/4885TSHR 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.